ClinConnect ClinConnect Logo
Search / Trial NCT06243757

A Study of Minimally Invasive Proximal Gastrectomy Versus Minimally Invasive Total Gastrectomy for Gastric and Gastroesophageal Junction Cancers

Launched by MEMORIAL SLOAN KETTERING CANCER CENTER · Jan 29, 2024

Trial Information

Current as of July 24, 2025

Active, not recruiting

Keywords

Gastric Cancer Non Metastatic Gastric Cancer Gastroesophageal Junction Adenocarcinoma Gastroesophageal Cancer Gej Adenocarcinoma Mipg Mitg Minimally Invasive Proximal Gastrectomy Minimally Invasive Total Gastrectomy 23 324 Memorial Sloan Kettering Cancer Center

ClinConnect Summary

This clinical trial is comparing two types of surgical procedures for patients with gastric cancer or cancer at the gastroesophageal junction. The study aims to find out whether a minimally invasive proximal gastrectomy (MIPG) or a minimally invasive total gastrectomy (MITG) is more effective for those diagnosed with this type of cancer. Participants will fill out a questionnaire a month before their surgery and then again at 1, 3, 6, and 12 months after the procedure to help researchers understand the outcomes and recovery experiences.

To be eligible for the study, participants must be at least 18 years old and have a confirmed diagnosis of non-metastatic gastric or gastroesophageal junction adenocarcinoma. They should also be able to read and understand English, Spanish, Japanese, or Korean. However, those with certain medical conditions, such as malabsorption syndromes or narcotic dependence, and pregnant individuals cannot participate. This trial is currently recruiting participants, and it offers an opportunity to contribute to important research while receiving standard care for their condition.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Able to speak and read English, Spanish, Japanese or Korean
  • Patients with a biopsy-confirmed diagnosis of non-metastatic gastric or GEJ adenocarcinoma, who are scheduled to undergo MIPG or MITG for curative-intention
  • Age ≥ 18
  • Exclusion Criteria:
  • Patients with known malabsorption syndromes or a lack of physical integrity of the upper gastrointestinal tract
  • Patients with known narcotic dependence, with average daily dose \> 5 mg oral morphine equivalent
  • Subjects deemed unable to comply with study and/or follow-up procedures, at investigators' discretion
  • Patients who are pregnant (since are excluded from receiving standard-of-care MIPG or MITG)

About Memorial Sloan Kettering Cancer Center

Memorial Sloan Kettering Cancer Center (MSKCC) is a world-renowned institution dedicated to cancer treatment, research, and education. As a leading clinical trial sponsor, MSKCC focuses on advancing innovative cancer therapies through rigorous scientific investigation and collaboration. The center's multidisciplinary team of experts employs cutting-edge methodologies to design and conduct trials that aim to improve patient outcomes and enhance understanding of cancer biology. With a commitment to translating research findings into clinical practice, MSKCC plays a pivotal role in shaping the future of oncology care and ensuring that patients have access to the latest therapeutic advancements.

Locations

New York, New York, United States

Harrison, New York, United States

Middletown, New Jersey, United States

Montvale, New Jersey, United States

Commack, New York, United States

Basking Ridge, New Jersey, United States

Rockville Centre, New York, United States

Houston, Texas, United States

Patients applied

0 patients applied

Trial Officials

Vivian Strong, MD

Principal Investigator

Memorial Sloan Kettering Cancer Center

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported